GluR8 Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GluR8 Protein</th>
</tr>
<tr>
<td class="label">Drug/Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">LY466365</td>
<td>GluR5/8 antagonist</td>
</tr>
<tr>
<td class="label">UBP310</td>
<td>GluR5/8 agonist</td>
</tr>
<tr>
<td class="label">LY382884</td>
<td>GluR5 antagonist</td>
</tr>
<tr>
<td class="label">ATPA</td>
<td>GluR5 agonist</td>
</tr>
</table>
Glur8 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The GluR8 protein (encoded by the GRIK4 gene) is a subunit of kainate-type glutamate receptors, also known as kainate receptor subunit 8 or GRIK4. It is one of five subunits (GRIK1-5) that combine to form functional kainate receptors. GluR8 has distinct pharmacological properties and is expressed in specific brain regions, playing important roles in synaptic transmission and circuit function.
Structure
Protein Domains
GluR8 exhibits several distinctive structural features:
...GluR8 Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GluR8 Protein</th>
</tr>
<tr>
<td class="label">Drug/Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">LY466365</td>
<td>GluR5/8 antagonist</td>
</tr>
<tr>
<td class="label">UBP310</td>
<td>GluR5/8 agonist</td>
</tr>
<tr>
<td class="label">LY382884</td>
<td>GluR5 antagonist</td>
</tr>
<tr>
<td class="label">ATPA</td>
<td>GluR5 agonist</td>
</tr>
</table>
Glur8 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
The GluR8 protein (encoded by the GRIK4 gene) is a subunit of kainate-type glutamate receptors, also known as kainate receptor subunit 8 or GRIK4. It is one of five subunits (GRIK1-5) that combine to form functional kainate receptors. GluR8 has distinct pharmacological properties and is expressed in specific brain regions, playing important roles in synaptic transmission and circuit function.
Structure
Protein Domains
GluR8 exhibits several distinctive structural features:
- High-affinity glutamate binding domain: The ligand-binding domain (LBD) of GluR8 shows the highest affinity for glutamate among all kainate receptor subunits, with Kd values in the sub-micromolar range<sup>[1]</sup>
- Distinct binding pocket: The ligand-binding pocket has unique amino acid residues that confer selective pharmacology compared to other GRIK subunits<sup>[1]</sup>
- Transmembrane domain: Four transmembrane segments (M1-M4) that form the ion channel pore
- C-terminal tail: Intracellular domain involved interactions and trafficking
Unique Pharmacology
GluR8 has several unique pharmacological properties:
- Highest kainate affinity: GRIK4-containing receptors in protein bind kainate with the highest affinity among all kainate receptor configurations
- LY382884 sensitivity: Particularly sensitive to the selective antagonist LY382884
- ATPA agonist: Responds uniquely to (2S,4R)-4-Phosphonomethyl-2-pyrrolidineacetic acid (ATPA), a GluR5-selective agonist
- Concanavalin A modulation: Uniquely modulated by concanavalin A in some splice variants
Splice Variants
Multiple splice variants of GluR8 have been identified:
- GluR8a: Full-length variant with highest expression in the hippocampus
- GluR8b: Truncated variant lacking the C-terminal domain
- GluR8c: Alternative splicing in the ligand-binding domain
Normal Function
High-Affinity Signaling
GluR8-containing kainate receptors serve unique physiological functions:
- Detection of low glutamate concentrations: Due to their high affinity, these receptors can detect ambient glutamate levels that do not activate AMPA or [NMDA](/entities/nmda-receptor) receptors, potentially mediating tonic excitatory signaling<sup>[2]</sup>
- Threshold control: May set the threshold for synaptic activation at specific terminals
- Volume transmission: Potentially responsive to extrasynaptic glutamate released via volume transmission
Synaptic Specialization
- Presynaptic localization: Often found at presynaptic terminals where they regulate neurotransmitter release
- Postsynaptic densities: Present at select postsynaptic sites, particularly in hippocampal CA3 pyramidal [neurons](/entities/neurons)
- Circuit-specific plasticity: Contributes to long-term depression (LTD) and [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) in specific neural circuits
Brain Region Distribution
GluR8 shows region-specific expression:
- [Hippocampus](/brain-regions/hippocampus): Highest expression in CA3 region and dentate gyrus granule cells
- Cerebral [cortex](/brain-regions/cortex): Layer-specific expression in cortical pyramidal neurons
- Amygdala: Moderate expression in basolateral amygdala
- Cerebellum: Low expression in Purkinje cells and granule cells
Molecular Mechanisms
Ion Channel Properties
- Conductance: Single-channel conductance of 0.8-1.2 pS
- Calcium permeability: Moderate calcium permeability compared to NMDA receptors
- Desensitization kinetics: Slow desensitization rate compared to other kainate receptors
- Recovery from desensitization: Fast recovery allowing high-frequency synaptic responses
Protein Interactions
GluR8 interacts with several proteins:
- PSD-95 family: SAP97 and PSD-95 can anchor GluR8 at synaptic sites
- GRIP/GRIP1: Links GluR8 to AMPA receptor subunits
- PICK1: Involved in GluR8 trafficking and endocytosis
- RACK1: Modulates channel assembly and function
Signaling Pathways
- MAPK/ERK pathway: GluR8 activation can trigger downstream kinase cascades
- cAMP/PKA signaling: Modulated by PKA phosphorylation
- Calcium-dependent cascades: Activates calmodulin and calcineurin
Disease Associations
Alzheimer's Disease
GluR8 plays a complex role in Alzheimer's disease:
- Altered cortical expression: Studies show decreased GRIK4 mRNA in AD prefrontal cortex<sup>[3]</sup>
- Excitotoxic vulnerability: Dysregulated glutamate signaling may contribute to excitotoxicity
- Therapeutic targeting: GluR5/8 antagonists explored as neuroprotective agents
- Cognitive function: Kainate receptor modulation may affect learning and memory
Depression
GluR8 has been implicated in depression and antidepressant response:
- Genetic variants: GRIK4 polymorphisms associated with major depressive disorder<sup>[4]</sup>
- Treatment response: Certain variants predict response to antidepressants
- Circuit function: Kainate receptors in hippocampus and amygdala affect mood regulation
- Therapeutic potential: GluR5/8 modulators under investigation for treatment-resistant depression
Epilepsy
- Seizure susceptibility: GRIK4 mutations linked to febrile seizures
- Anticonvulsant targets: Kainate receptor antagonists have anti-seizure properties
- Temporal lobe epilepsy: Altered expression in hippocampus of TLE patients
Schizophrenia
- Genetic association: GRIK4 variants linked to schizophrenia risk
- Cognitive deficits: Kainate receptor dysfunction may contribute to cognitive impairment
- Postmortem studies: Altered GRIK4 expression in prefrontal cortex
Therapeutic Implications
Drug Development
Several therapeutic strategies target GluR8:
Challenges
- Subunit selectivity: Achieving selective antagonism is challenging due to similar binding sites
- [Blood-brain barrier](/entities/blood-brain-barrier): Drug delivery to CNS remains a challenge
- Side effects: Motor and cognitive effects limit therapeutic window
Research Directions
- Structure-based drug design: Using cryo-EM structures for rational drug development
- Gene therapy: Viral vector delivery of GRIK4 modulators
- Biomarkers: GRIK4 expression as a biomarker for CNS disorders
- Personalized medicine: Genetic testing for GRIK4 variants to guide treatment
Animal Models
Knockout Studies
- GRIK4-/- mice: Show altered hippocampal synaptic plasticity
- Behavioral phenotypes: Deficits in spatial memory and fear conditioning
- Seizure models: Increased susceptibility to chemoconvulsants
Transgenic Models
- Overexpression studies: Human GRIK4 transgenic mice show cognitive changes
- Conditional knockouts: Region-specific deletion reveals circuit-specific functions
See Also
- [GRIK4 Gene](/grik4-gene)
- [GluR5 Protein](/proteins/glur5-protein)
- [GluR6 Protein](/proteins/glur6-protein)
- [GluR7 Protein](/proteins/glur7-protein)
- [Kainate receptors](/entities/kainate-receptors)
- [Glutamate receptors](/entities/glutamate-receptors)
- [Ionotropic glutamate receptors](/entities/ionotropic-glutamate-receptors)
- [AMPA receptors](/entities/ampa-receptors)
- [NMDA receptors](/entities/nmda-receptors)
External Links
- [UniProt: GluR8](https://www.uniprot.org/uniprot/P39088)
- [Human Protein Atlas](https://www.proteinatlas.org/ENSG00000179458-GRIK4)
- [IUPHAR/BPS Guide to Pharmacology](https://www.guidetopharmacology.org/target/1583)
- [PubMed: GRIK4](https://pubmed.ncbi.nlm.nih.gov/?term=GRIK4+kainate+receptor)
Background
The study of Glur8 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
<sup>[1]</sup> [GluR8 pharmacology and function. British Journal of Pharmacology, 2016](https://pubmed.ncbi.nlm.nih.gov/26858136)
<sup>[2]</sup> [High-affinity kainate receptors in cognition. Neuropharmacology, 2018](https://pubmed.ncbi.nlm.nih.gov/29392417)
<sup>[3]</sup> [Altered glutamate receptor expression in Alzheimer's disease. Journal of Alzheimer's Disease, 2019](https://pubmed.ncbi.nlm.nih.gov/31178025)
<sup>[4]</sup> [GRIK4 variants in depression. Translational Psychiatry, 2019](https://pubmed.ncbi.nlm.nih.gov/31092931)
<sup>[5]</sup> [Kainate receptors in brain disorders. Nature Reviews Neurology, 2020](https://pubmed.ncbi.nlm.nih.gov/32184552)
<sup>[6]</sup> [Selective kainate receptor modulators. Expert Opinion on Therapeutic Targets, 2021](https://pubmed.ncbi.nlm.nih.gov/33748912)
<sup>[7]</sup> [GRIK4 and psychiatric disorders. Molecular Psychiatry, 2020](https://pubmed.ncbi.nlm.nih.gov/32807938)
<sup>[8]</sup> [Kainate receptor trafficking. Journal of Neuroscience, 2017](https://pubmed.ncbi.nlm.nih.gov/28539345)